Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca releases top-line results from Phase IIIb Saturn trial
The results of the trial suggested that the tolerability and efficacy of Crestor seen in Saturn were in line with previous studies and approved product labelling. The results
The results of the trial suggested that the tolerability and efficacy of Crestor seen in Saturn were in line with previous studies and approved product labelling. The results
The allowance further strengthens the Marina’s nucleic acid-peptide drug delivery platform and expands the patent protection for its comprehensive set of nucleic acid delivery technologies. The patent application
The Thermo Scientific HyClone SUB will start shake-down runs and is expected to be ready for GMP contract manufacturing by December 2011. CMC Biologics global chief operations officer
iMedNet EDC facilitates non-technical research personnel to construct and engage their own clinical studies. MedNet Solutions president and CEO John Robertson said iMedNet provides the entire life sciences
The decision was backed by the issuance of a complete response letter (CRL) by the US Food and Drug Administration (FDA) for Pariet/AcipHex ER capsules’ new drug application
The results from Phase 3 trials demonstrated improvement in erectile function in comparison to placebo. The avanafil development program included over 1,350 patients and avanafil was shown to
As per the terms of the agreement, Synageva is eligible to receive an upfront payment of $3m from Mitsubishi Tanabe. Additionally, Mitsubishi Tanabe will contribute additional research funds.
The PMS software provides a data entry portal integrated with the ability to handle data transformation, data imports and exports, analysis and generating customized reports as per client
The new patent covers methods for determining the presence or absence of a fetal aneuploidy, or an abnormal number of fetal chromosomes, by analysis of blood samples from
Nuedexta is indicated for the treatment of pseudobulbar affect (PBA). Impax has submitted a new drug application (ANDA) containing a paragraph IV certification for a generic version of